Evidence-graded peptide medicine resources covering BPC-157, CJC-1295, ipamorelin, TB-500, sermorelin, tesamorelin, safety, access, monitoring, and protocol design. Peptide therapy is the medical use of peptides, short chains of amino acids that act as signals in the body. Some peptides are well-established medicines, while others are still being researched, and they are used to target specific goals rather than as a single treatment. Peptides sit between small drug molecules and large proteins. Because they often mimic the body's own signaling molecules, they are studied across many areas of medicine, from metabolism to immune function. How does peptide therapy work? Each peptide works differently. Some, like GLP-1 medications, mimic gut hormones; others, like sermorelin, prompt a gland to release its own hormone; and some, like BPC-157, are studied as repair signals. The right peptide depends entirely on the goal. What are peptides used for? Peptides are studied across several areas of health. The evidence is strongest for FDA-approved medicines and weaker for research compounds, so the use case matters as much as the molecule. Weight and metabolism: GLP-1 medicines (semaglutide, tirzepatide), tesamorelin, AOD-9604. Healing and recovery: BPC-157, GHK-Cu. Growth-hormone support: sermorelin, tesamorelin. Skin and hair: GHK-Cu, glutathione. Focus, mood, and sleep: semax, selank. Sexual wellness: PT-141. Longevity and energy: NAD+, epitalon. Immune support: thymosin alpha-1. Is peptide therapy safe and legal? Safety and legal status vary widely by peptide. A few are FDA approved, many are not, and some have had their compounding restricted. Peptides are prescription only, and product quality and sterility matter, so a licensed provider and a reputable pharmacy are essential. How do you get peptide therapy online? Peptide therapy through an online clinic like HealthRX.com starts with an evaluation by a licensed provider, who reviews your history and goals and, if appropriate, writes a prescription. The peptide is then prepared by a licensed compounding pharmacy and shipped to you. Peptides should not be used without medical oversight. Because peptides are prescription only, a legitimate telehealth clinic will always require a provider visit before dispensing. You can complete that visit online, and each molecule guide below links to the specific peptide, its evidence, and how to start. How much does peptide therapy cost? Peptide therapy is usually priced per vial or per monthly course rather than through insurance, since most peptides are compounded. The cost depends on the specific molecule, the dose, and the quantity your provider recommends. At HealthRX.com, individual peptide vials are commonly in the low hundreds of dollars, with per-vial pricing that decreases at larger quantities. Compounded and blended protocols are priced separately. Each molecule guide shows the current starting price and lets you begin an online visit. Peptide guides by molecule KPV kpv peptide SS-31 ss-31 peptide DSIP dsip peptide Oxytocin Nasal Spray oxytocin nasal spray NAD+ nad+ injection Glutathione glutathione injection AOD-9604 aod-9604 BPC-157 bpc 157 Sermorelin sermorelin Tesamorelin tesamorelin MOTS-c mots-c peptide Epitalon epitalon Thymosin Alpha-1 thymosin alpha 1 Frequently asked questions Peptide therapy is the medical use of peptides, short amino-acid chains that act as signals in the body, to target specific goals such as metabolism, recovery, or immune support. Some peptides are FDA approved, such as semaglutide and tesamorelin, while many others are not. Each peptide has its own regulatory status, so it should be judged individually. Safety varies by peptide and by the evidence behind it. Peptides are prescription only and should be used under a licensed provider with a reputable pharmacy. You start with an evaluation by a licensed provider, who can write a prescription if appropriate; the peptide is then prepared by a licensed compounding pharmacy. Cost depends on the molecule, dose, and quantity. Most peptides are compounded and priced per vial or monthly course rather than through insurance, with individual vials commonly in the low hundreds of dollars and lower per-vial pricing at larger quantities. The strongest evidence for weight loss is for GLP-1 medicines like semaglutide and tirzepatide. Some other peptides are marketed for fat loss with much weaker evidence. High-intent clinical paths What Is DSIP? The Delta Sleep-Inducing Peptide, Explained DSIP (emideltide) is a 1970s rabbit-brain-derived peptide with no FDA-approved use and thin, mostly small or animal-based sleep evidence. What Is Selank? The Tuftsin-Based Anxiolytic Peptide Selank is a synthetic heptapeptide derived from tuftsin, studied mainly in Russian labs for anxiety and cognition, with no FDA-approved use. Editorial: KPV's Evidence Is Better Than Most Peptides', and Still Not Enough KPV has more mechanistic and animal data than most research peptides, but human trials are absent and no FDA enforcement discretion covers compounding it as of Sept 2026. Browse by clinical intent Performance and Recovery BPC-157, TB-500, tendon recovery, post-surgical protocols, injury questions, and evidence tradeoffs. Stacking KPV with BPC-157: Rationale and Cautions KPV vs BPC-157 for Gut Health: Different Tools, Different Jobs KPV vs TB-500: Comparing Two Post-Category-2 Peptides FDA Peptide Status Tracker: Category 2, PCAC Votes, and 503A (2026) BPC-157 Complete Drug-Drug Interaction Profile Growth Hormone Axis CJC-1295, ipamorelin, sermorelin, tesamorelin, MK-677, IGF-1 effects, and monitoring. Egrifta (Tesamorelin) and Estradiol HRT Interaction: Safety, Risks, and Clinical Guidance Egrifta (Tesamorelin) and Trazodone Interaction: Safety, Risks, and Clinical Guidance CJC-1295 for Sarcopenia in Older Adults: A Clinical Protocol Peptide with TRT: What the Evidence Says About Combining Peptides and Testosterone CJC-1295 Mechanism of Action: Full Pathway From Injection to IGF-1 Output Safety and Monitoring Drug interactions, renal and hepatic considerations, pregnancy, adverse effects, and clinical guardrails. BPC-157 Complete Drug-Drug Interaction Profile Egrifta (Tesamorelin) and Estradiol HRT Interaction: Safety, Risks, and Clinical Guidance Egrifta (Tesamorelin) and Trazodone Interaction: Safety, Risks, and Clinical Guidance TB-500 Overdose and Accidental Excess Dose: Recognition, Risks, and Clinical Management TB-500 Renal Protection or Renal Risk: What the Evidence Actually Shows Peptide Medicine explorer Showing 300 of 2,371 clinical reviews. What Is DSIP? The Delta Sleep-Inducing Peptide, Explained DSIP (emideltide) is a 1970s rabbit-brain-derived peptide with no FDA-approved use and thin, mostly small or animal-based sleep evidence. What Is Selank? The Tuftsin-Based Anxiolytic Peptide Selank is a synthetic heptapeptide derived from tuftsin, studied mainly in Russian labs for anxiety and cognition, with no FDA-approved use. Editorial: KPV's Evidence Is Better Than Most Peptides', and Still Not Enough KPV has more mechanistic and animal data than most research peptides, but human trials are absent and no FDA enforcement discretion covers compounding it as of Sept 2026. KPV Nanoparticle Delivery: The Research That Changed Oral Peptides Why hyaluronic-acid and nanoparticle KPV delivery matters for gut-targeted peptides, based on murine colitis studies, not human trials. Stacking KPV with BPC-157: Rationale and Cautions KPV plus BPC-157 is a compounding-community practice with no direct combination trials. Here's the mechanistic rationale and what remains unproven. KPV vs BPC-157 for Gut Health: Different Tools, Different Jobs KPV and BPC-157 both get used for gut inflammation, but their evidence and mechanisms differ. Here is how they compare and where each is unproven. KPV vs TB-500: Comparing Two Post-Category-2 Peptides KPV and TB-500 both lost FDA Category 2 nomination status and got favorable PCAC votes, but neither is FDA-approved or on the 503A list as of Sept 2026. FDA Peptide Status Tracker: Category 2, PCAC Votes, and 503A (2026) Live reference table tracking FDA regulatory status for 18 compounded peptides: Category 2 placements, withdrawals, PCAC votes, and 503A bulks list status. BPC-157 Complete Drug-Drug Interaction Profile What is actually known about BPC-157 drug interactions, including the absence of formal human interaction studies and the limits of animal evidence. Egrifta (Tesamorelin) and Estradiol HRT Interaction: Safety, Risks, and Clinical Guidance What is known and unknown about using tesamorelin with estradiol, including label-based risks, growth-hormone biology, and questions for the prescribing team. Egrifta (Tesamorelin) and Trazodone Interaction: Safety, Risks, and Clinical Guidance What current labeling and interaction resources establish about tesamorelin with trazodone, what remains unknown, and which patient-specific risks require review. BPC-157 for Wound Healing: Off-Label Risks, Benefits, and What the Evidence Actually Shows

BPC-157 has no FDA-approved wound-healing use. This guide separates preclinical interest from the human evidence and explains when a wound needs clinical care. TB-500 Overdose and Accidental Excess Dose: Recognition, Risks, and Clinical Management What to do after a suspected TB-500 dosing error, why no human toxic dose is established, and how product uncertainty changes emergency assessment. TB-500 Renal Protection or Renal Risk: What the Evidence Actually Shows What is known---and not known---about TB-500 (thymosin beta-4 fragment), kidney claims, and regulatory status. BPC-157 vs GHK-Cu: Switching Between Them A clinical comparison of BPC-157 pentadecapeptide and copper tripeptide GHK-Cu, including mechanisms, evidence, and practical guidance on switching between them. CJC-1295 Manufacturer Copay Program: How to Lower Your Cost in 2026 There is no manufacturer copay card for CJC-1295. Check its FDA status, verify any pharmacy, compare written cash quotes, and confirm HSA or FSA rules before paying. BPC-157 Adolescent (12 to 17) Dosing: What Clinicians and Parents Need to Know There is no validated BPC-157 dose for adolescents. Review the current FDA evidence, July 2026 compounding review, athlete rules, and safer next steps. CJC-1295 for Sarcopenia in Older Adults: A Clinical Protocol What human studies actually show about CJC-1295 for age-related muscle loss, how sarcopenia is diagnosed, and which exercise and nutrition treatments have clinical evidence. Peptide with TRT: What the Evidence Says About Combining Peptides and Testosterone A guide to the evidence and safety gaps for combining testosterone replacement therapy with CJC-1295, ipamorelin, BPC-157, TB-500, sermorelin, or bremelanotide. TB-500 Safety Signals and FDA Actions: What Patients and Clinicians Need to Know A source-verified review of TB-500 safety, FDA actions, human evidence, compounding status, product-quality risks, adverse-event reporting, and anti-doping rules. Sermorelin Online: How to Get It, What It Costs, and Who It Actually Helps A guide to getting sermorelin online, covering telehealth candidacy screening, compounded pricing, prescription requirements, and an honest look at the underlying trial evidence. Egrifta (Tesamorelin) Online: Cost, Candidacy, and What the Evidence Shows A guide to getting Egrifta (tesamorelin) online, including real pricing, telehealth steps, candidacy criteria, and trial data from Falutz et al. (NEJM 2007). GHK-Cu Online: Cost, Candidacy, and How to Get It Through Telehealth A guide to getting GHK-Cu online: what the peptide research actually shows, who qualifies, what it costs per month, and how the telehealth prescribing process works. Epitalon Online: Cost, Prescription Requirements, and What the Research Actually Shows A guide to getting Epitalon online: candidacy, typical cost, the telehealth prescription process, and an honest look at the evidence behind this investigational peptide. MOTS-c Online: Cost, Candidacy, and How the Telehealth Process Works A clear, evidence-graded guide to getting MOTS-c through telehealth: what the peptide is, what the 2015 Cell Metabolism study actually showed, realistic cost, and how a prescriber decides if it fits you. TB-500 Patient Assistance for Low-Income: How to Reduce Your Out-of-Pocket Cost TB-500 (thymosin beta-4 fragment) is not covered by insurance or traditional patient assistance programs. Learn realistic strategies to lower your cost for this compounded peptide. Superpower Real Customer Outcomes: An Independent Review of Lab, GLP-1, and Peptide Services Independent analysis of Superpower's subscription concierge model for lab testing, GLP-1 prescriptions, and peptide therapies. Real customer outcomes, pricing, clinical evidence, and how Superpower compares to alternatives. Andrew Huberman Peptides: How a Regular Patient Would Get Access Andrew Huberman has discussed BPC-157, TB-500, and growth hormone secretagogues on his podcast. Here is how an ordinary patient can legally access peptides through licensed clinicians, what the FDA allows, and what the evidence actually supports. Andrew Huberman, Peptides, and the Ethics of Celebrity Rx Disclosure A clinical and journalistic analysis of Andrew Huberman's public peptide discussions, the ethics of celebrity health disclosure, and what his influence means for patient safety and informed consent. Jeremy Allen White and Peptides: A Clinical Interpretation of The Bear Star's Physique A clinical breakdown of the peptide speculation surrounding Jeremy Allen White's physique transformation, what the science says about growth-hormone peptides, and how to separate celebrity gossip from evidence-based medicine. Jeremy Allen White and Peptides: What He Has Actually Said About Medication A clinical look at Jeremy Allen White's public statements on peptides, supplements, and medication. We separate verified quotes from speculation and explain the peptide science behind physique transformations like his. Jeremy Allen White Transformation Timeline: What We Know About His Physique, Training, and Peptide Speculation A clinical look at Jeremy Allen White's physical transformation for The Bear and the Bruce Springsteen biopic, what he has confirmed about his training, and what the peptide speculation actually involves. CJC-1295 Mechanism of Action: Full Pathway From Injection to IGF-1 Output A physician-level breakdown of how CJC-1295 (modified GRF 1-29) activates GHRH receptors, amplifies pulsatile GH release, and sustains IGF-1 elevation for up to 8 days through Drug Affinity Complex albumin binding. CJC-1295 Monitoring Schedule: Labs and Exams You Need A clinician-grade monitoring schedule for CJC-1295 (modified GRF 1-29), covering baseline labs, follow-up intervals, IGF-1 targets, safety markers, and when to adjust or discontinue therapy. CJC-1295 Pharmacogenomics: How Genetic Variability Affects Growth Hormone Response How pharmacogenomics and genetic variants in GHRHR, GH1, IGF1, and SOCS genes shape individual responses to CJC-1295 modified GRF. Evidence-based guide for clinicians and patients. Copper Peptides Drug-Drug Interaction Table: A Prescriber and Pharmacist Reference Complete drug-drug interaction (DDI) table for the copper peptides class, centered on GHK-Cu. Covers topical and systemic formulations, chelation conflicts, retinoid co-use, and monitoring guidance for polypharmacy patients. Copper Peptides Monitoring Bundle: Lab Panels, Schedules, and Clinical Thresholds for GHK-Cu Prescribers Evidence-based monitoring protocol for copper peptide (GHK-Cu) therapy covering baseline labs, ongoing surveillance intervals, serum copper and ceruloplasmin targets, hepatic panels, and discontinuation criteria for prescribing clinicians. Healing Peptides (BPC-157 / TB-500) Adverse-Event Management Protocols Evidence-based adverse-event management protocols for BPC-157 and TB-500 healing peptides, including grading scales, clinical decision points, dose modifications, and when to discontinue therapy. Healing Peptides (BPC-157 / TB-500) Drug-Drug Interaction Table Clinician-focused drug-drug interaction reference for BPC-157 and TB-500 healing peptides, covering known pharmacologic interactions, CYP considerations, and co-prescribing precautions. Healing Peptides (BPC-157 / TB-500): Special-Populations Prescribing Summary Evidence-based special-populations guide for BPC-157 and TB-500 (thymosin beta-4). Covers renal impairment, hepatic dysfunction, pediatrics, geriatrics, pregnancy, lactation, and immunocompromised patients at MD/PharmD level. CJC-1295 vs MK-677 (Ibutamoren): Cost and Access Head-to-Head A detailed cost and access comparison of CJC-1295 (modified GRF) and MK-677 (ibutamoren) for growth hormone optimization, including pricing, insurance coverage, compounding pharmacy availability, and clinical efficacy data. CJC-1295 vs MK-677 (Ibutamoren): How to Switch Between Them Safely Compare CJC-1295 (modified GRF 1-29) and MK-677 (ibutamoren) for growth hormone optimization. Learn switching protocols, clinical differences, and which peptide fits your goals. Ipamorelin vs CJC-1295: Cost and Access Head-to-Head Compare ipamorelin acetate and CJC-1295 (modified GRF 1-29) on price per vial, insurance barriers, pharmacy access, and clinical evidence for growth hormone release. Sermorelin vs CJC-1295: How to Switch Between Them Safely A clinical comparison of sermorelin acetate and CJC-1295 (modified GRF 1-29), including pharmacokinetics, efficacy data, and a step-by-step protocol for switching between these GHRH analogs. Sermorelin vs Egrifta (Tesamorelin): Switching Between Them A clinical comparison of sermorelin acetate and tesamorelin (Egrifta), including mechanisms, trial data, and practical guidance for switching between these GHRH analogs. Egrifta (Tesamorelin) vs MK-677 (Ibutamoren): Switching Between Them Clinical comparison of tesamorelin and ibutamoren (MK-677) for growth hormone optimization, including when and how to switch between these two peptides safely. AOD-9604 vs MOTS-c: Switching Between These Peptides A clinical comparison of AOD-9604 (HGH fragment 176-191) and MOTS-c mitochondrial peptide, including when and how to switch between them safely. PT-141 (Bremelanotide) vs AOD-9604: Switching Between Them Clinical comparison of PT-141 (bremelanotide) and AOD-9604 (HGH fragment 176-191), including mechanisms, indications, side effects, and how to switch safely between these specialty peptides. Epitalon Cost vs. Alternatives: What You Actually Pay for Telomerase-Targeting Peptides A clinical comparison of epitalon tetrapeptide pricing against TA-65, GHK-Cu, NAD+ precursors, and other longevity-class compounds, with mechanism breakdowns and evidence grading. BPC-157 Safety in Black / African Ancestry Patients: What the Evidence Actually Shows BPC-157 pentadecapeptide lacks ethnicity-stratified human trial data. This article covers pharmacogenomic factors, G6PD considerations, renal risk, and monitoring guidance for Black / African ancestry patients considering BPC-157. BPC-157 in South Asian Patients: Documented Efficacy Gaps and Pharmacogenomic Considerations Evidence review of BPC-157 pentadecapeptide efficacy in South Asian populations, covering pharmacogenomic variability, dosing considerations, and documented gaps in ethnicity-stratified clinical data. BPC-157 Safety Profile Differences in South Asian Patients Evidence-based review of BPC-157 pentadecapeptide safety considerations for South Asian individuals, including pharmacogenomic factors, cardiovascular risk at lower BMI thresholds, and dosing guidance. CJC-1295 Black / African Ancestry Dose Adjustments Evidence-based guide to CJC-1295 modified GRF dosing considerations for Black and African ancestry patients, including pharmacogenomic factors, GH axis variability, and clinical monitoring protocols. CJC-1295 Safety Profile Differences in South Asian Patients Evidence-based review of CJC-1295 (modified GRF 1-29) safety considerations for South Asian populations, including pharmacogenomic variation, cardiovascular risk at lower BMI thresholds, and clinical monitoring adjustments. Ipamorelin Efficacy in Black and African Ancestry Patients: Documented Gaps and Pharmacogenomic Considerations Evidence review of ipamorelin acetate efficacy differences in Black and African ancestry populations, covering pharmacogenomics, GH axis variability, GHSR polymorphisms, and race-stratified clinical data gaps. Ipamorelin East Asian Dose Adjustments: Pharmacogenomics, Body Composition, and Clinical Guidance Evidence-based guide to ipamorelin acetate dosing in East Asian patients, covering pharmacogenomics, BMI thresholds, GH-axis variation, and practical dose-adjustment strategies. Ipamorelin South Asian Dose Adjustments Evidence-based guide to ipamorelin acetate dosing considerations for South Asian patients, covering pharmacogenomics, metabolic phenotype differences, body composition factors, and clinical monitoring protocols. TB-500 South Asian Dose Adjustments: Pharmacogenomic and Clinical Considerations Evidence-based guide to TB-500 (thymosin beta-4 active fragment) dosing considerations for South Asian patients, covering pharmacogenomics, body composition differences, and monitoring protocols. TB-500 South Asian Documented Efficacy Gaps: Pharmacogenomics, Dosing, and What the Evidence Actually Shows TB-500 (thymosin beta-4 active fragment) may behave differently in South Asian patients due to cardiovascular risk profiles, metabolic differences, and pharmacogenomic variation. Here is what the clinical and preclinical data reveal. TB-500 in South Asian Patients: Safety Profile Differences and Pharmacogenomic Considerations Evidence-based analysis of TB-500 (thymosin beta-4 active fragment) safety differences in South Asian populations, covering pharmacogenomics, cardiovascular risk modifiers, dosing considerations, and monitoring protocols. Showing the first 60 matches. Use search or filters to narrow the library.